Indications, Safety, and Warnings
Indications (or intended use)
Micra™ devices, Micra™ Model MC1VR01 and Micra™ AV Model MC1AVR1, are indicated for use in patients who have experienced one or more of the following conditions:
Paroxysmal or permanent high-grade AV block in the presence of AF
Paroxysmal or permanent high-grade AV block in the absence of AF, as an alternative to dual chamber pacing, when a dual chamber transvenous pacing system is considered difficult, high risk, or not deemed necessary for effective therapy
Symptomatic bradycardia-tachycardia syndrome or sinus node dysfunction (sinus bradycardia or sinus pauses), as an alternative to atrial or dual chamber pacing, when a dual chamber transvenous pacing system is considered difficult, high risk, or not deemed necessary for effective therapy
Micra™ AV Model MC1AVR1 is also indicated for VDD pacing in patients with adequate sinus rates who may benefit from maintenance of AV synchrony. The Micra™ AV device provides AV synchronous ventricular pacing like a transvenous VDD system. The implanted device depends on the appropriate sensing of atrial mechanical signals to achieve AV synchrony. The level of AV synchrony may vary in individual patients and may not be predictable prior to implant.
Rate-responsive pacing is indicated to provide increased heart rate appropriate to increasing levels of activity.
The device is designed to be used only in the right ventricle.
Warnings and precautions
End of service (EOS)
When the EOS condition is met, the clinician has the option of permanently programming the device to off and leaving it in the heart, or retrieving the device, provided the device has not yet become encapsulated. Removal of the Micra™ device after it has become encapsulated may be difficult because of the development of fibrotic tissue. If removal of the device is required, it is recommended that the removal be performed by a clinician who has expertise in the removal of implanted leads.
MRI conditions for use
Before an MRI scan is performed on a patient implanted with the Micra™ device, the cardiology and radiology professionals involved in this procedure must understand the requirements specific to their tasks as defined in the device manuals.
Rate-responsive mode may not be appropriate for patients who cannot tolerate pacing rates above the programmed lower rate. For Micra™ Model MC1VR01, asynchronous VVIR pacing with sinus rhythm may not be appropriate when competitive pacing is considered undesirable or causes symptoms of pacemaker syndrome. The patient’s age and medical condition should be considered by physicians and patients as they select the pacing system, mode of operation, and implant technique best suited to the individual.
Precautions should be taken before administering anticoagulant agents, antiplatelet agents, or contrast media in patients with known hypersensitivity to these agents.
The use of deactivated Micra™ devices in situ and an active Micra™ device, or an active transvenous pacemaker or defibrillator, has not been clinically tested to determine whether EMI or physical interaction is clinically significant. Bench testing supports that implantation of an active Micra™ device, or an active transvenous pacemaker or defibrillator, next to an inactivated Micra™ device is unlikely to cause EMI or physical interaction. Post-approval studies are planned to characterize risks of co-implanted, deactivated Micra™ devices. Currently recommended end of device life care for a Micra™ device may include the addition of a replacement device with or without explanation of the Micra™ device, which should be turned off.
For Micra™ AV Model MC1AVR1, patient activities and environments which present mechanical vibrations to the patient can interfere with the mechanical sensing of atrial contractions. This can result in a loss of AV synchrony.
Potential adverse events or potential complications
Potential complications include, but are not limited to, toxic/allergic reaction, oversensing, pacemaker syndrome, cardiac arrest, acceleration of tachycardia, necrosis, myocardial infarction and surgical complications such as cardiac perforation, pericardial effusion, cardiac tamponade, device embolization, hematoma, AV fistula, vessel dissection, infection, cardiac inflammation, and thrombosis.
See the device manuals for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, MRI conditions for use, and potential complications/adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult the Medtronic website at medtronic.com.
Caution: Federal law (United States) restricts these devices to sale by or on the order of a physician.
Micra™ VR2 leadless pacemaker
Micra™ VR leadless pacemaker
Micra™ AV2 leadless pacemaker